Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00232798 · 2 trials · 2 indications
Viral load was determined using the Roche COBAS Taqman HIV-1 assay with a lower limit of detection of 40 copies per milliliter (copies/mL). Samples with an initial reading of less than 1,000,000 copies/mL were diluted into range and re-assayed.
| Arm | Type | Description |
|---|---|---|
| PF-00232798 40 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 300 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 400 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 5 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 20 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 150 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 supratherapeutic dose | EXPERIMENTAL | PF-00232798 supratherapeutic dose |
| PF-00232798 therapeutic dose | EXPERIMENTAL | PF-00232798 therapeutic dose |
| Placebo for PF-00232798 | PLACEBO_COMPARATOR | Placebo for PF-00232798 |
| Moxifloxacin | ACTIVE_COMPARATOR | Moxifloxacin |
| Name | Type | Description |
|---|---|---|
| PF-00232798 | DRUG | Solution, 20 mg. once daily, 10 days |
| Placebo | DRUG | Oral solution once daily x 7 days |
| Moxifloxacin | DRUG | 400 mg tablet single dose |
Inclusion Criteria: * Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive. * Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay. Exclusion Criteria: * Patients who have received any experimental drug within the past four months...
PF-00232798 is an investigational small molecule being studied for the treatment of HIV. It is being developed by Pfizer, Inc. (PFE) for infectious disease. The drug has been evaluated in a Phase 2 clinical trial in HIV positive patients, but it is not approved and remains in clinical development.
PF-00232798 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company has conducted clinical trials of the drug in HIV positive patients and in healthy subjects. Pfizer is the sole developer of this investigational small molecule.
PF-00232798 is in Phase 2 clinical development. It has completed a Phase 2 study in HIV positive patients and a Phase 1 study in healthy subjects. The drug is investigational and has not been approved by regulatory authorities. No active trials are currently listed for this asset.
PF-00232798 has been studied in two completed trials. NCT00495677 was a Phase 2 study in 43 HIV positive male patients in Germany. NCT01140425 was a Phase 1 study in 44 healthy subjects in Singapore to evaluate the effect of multiple oral doses on QT intervals. Both trials are completed.
No alternative names for PF-00232798 have been disclosed. The drug is identified solely by its development code PF-00232798 in clinical trial records. It is an investigational small molecule being studied for HIV and has no known brand name or other aliases.